eFFECTOR is pioneering the field of Selective Translation Regulator Inhibitors (STRIs). Transcription is the copying of DNA sequences into mRNA, whereas translation is the subsequent utilization of mRNA sequences to direct protein synthesis.

eFFECTOR’s translation regulation targets are at a key node where oncogenic signaling pathways converge to impact multiple complementary cancer growth and survival mechanisms.

The importance of translation regulation in disease is becoming increasingly recognized in the pharmaceutical industry, and we believe we are at the forefront of developing novel approaches to cancer therapy focused on STRIs. Utilizing our proprietary selective translation regulation technology platform and expertise, we have developed an understanding of genes that are translationally upregulated in multiple tumor types. This has enabled us to identify specific points of therapeutic intervention that may have a meaningful clinical effect.


Our programs target three distinct targets central to the eIF4F translation initiation complex: MNK, eIF4A and eIF4E. Each of these targets regulates distinct sets of genes in cancer and immune cells.





The eIF4F complex plays a critical role in the production of certain proteins that promote cell growth, division and survival. eIF4F is a central junction where two of the most frequently activated signaling pathways in cancer, the PI3K-AKT and RAS-MEK pathways, converge. It is a central node that initiates the translation of the proteins that are frequent culprits in key disease-driving processes.

Activation of growth signaling pathways such as receptor tyrosine kinase (RTK) pathways, along with downstream PI3K-AKT and RAS-MEK pathways, converges on eIF4F and initiates over-production of multiple pro-growth proteins. Especially high activation of these growth signaling pathways can cause eIF4F activation that is excessive and continuous, resulting in upregulation of protein synthesis. This upregulation leads to uncontrolled growth of tumor cells, as well as exhaustion of T cells – causing T cells to become less effective cancer fighters.

eIF4F complex controls production of multiple cancer driving proteins simultaneously MNK eIF4A eIF4G eIF4E eIF4F COMPLEX


No more publications to show